Means Investment CO. Inc. Has $1.69 Million Position in Hims & Hers Health, Inc. $HIMS

Means Investment CO. Inc. reduced its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 10.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,958 shares of the company’s stock after selling 3,871 shares during the quarter. Means Investment CO. Inc.’s holdings in Hims & Hers Health were worth $1,693,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of HIMS. Northern Trust Corp boosted its holdings in Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after purchasing an additional 397,310 shares during the period. Yong Rong HK Asset Management Ltd increased its position in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after purchasing an additional 700,100 shares in the last quarter. Nuveen LLC acquired a new position in shares of Hims & Hers Health during the first quarter worth $58,403,000. BIT Capital GmbH raised its position in Hims & Hers Health by 7.4% in the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after purchasing an additional 112,949 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Hims & Hers Health by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after buying an additional 15,339 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the business’s stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares in the company, valued at approximately $8,581,970. The trade was a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 11,595 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $57.72, for a total value of $669,263.40. Following the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $4,053,791.04. This represents a 14.17% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,622,741 shares of company stock worth $83,695,469. Company insiders own 13.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Saturday, September 27th. Finally, Truist Financial decreased their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Trading Down 7.3%

NYSE HIMS opened at $53.98 on Friday. The firm has a market cap of $12.20 billion, a PE ratio of 67.48, a price-to-earnings-growth ratio of 3.64 and a beta of 2.25. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock has a 50-day moving average of $50.86 and a 200-day moving average of $48.00. Hims & Hers Health, Inc. has a 1-year low of $17.36 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the company posted $0.06 earnings per share. The firm’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.